Identification

Name
Morniflumate
Accession Number
DB09285
Type
Small Molecule
Groups
Approved
Description

Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid [8]. In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with bronchitis showed improvement [1].

Structure
Thumb
Synonyms
Not Available
External IDs
UP 164
Categories
UNII
R133MWH7X1
CAS number
65847-85-0
Weight
Average: 395.382
Monoisotopic: 395.145676005
Chemical Formula
C19H20F3N3O3
InChI Key
LDXSPUSKBDTEKA-UHFFFAOYSA-N
InChI
InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)
IUPAC Name
2-(morpholin-4-yl)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylate
SMILES
FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OCCN2CCOCC2)=CC=C1

Pharmacology

Indication

Morniflumate is indicated for the treatment of inflammatory conditions affecting the airways, ENT system, urogenital tract and bone and joint systems in adults. In Italy, morniflumate is also indicated for the treatment of pain associated with ear, nose, throat (ENT) and gastrointestinal inflammatory conditions in children. Morniflumate is a well established NSAID that has been in use for over three decades in Italy (particularly for the treatment of upper respiratory tract infections in children), France, Belgium, Austria, Switzerland, Spain and Portugal; it has a generally favorable tolerability profile.

Pharmacodynamics

Morniflumate, given at therapeutic dosages to healthy human volunteers, on leukotriene B4 (LTB4) and thromboxane (TXB2) synthesis, both in purified PMNs (polymorphnuclear neutrophils) and in whole blood [1].

In whole blood experiments, morniflumate reduced blood leukotriene B4 (LTB4) synthesis induced by Ca-ionophore A23187 Bx approximately 50%, both after a single dose and at steady state; the level of inhibition showed a pattern similar to the plasma levels of the bioactive metabolite of morniflumate (M1). The inhibition of serum thromboxane B2 (TXB2) levels was higher than 85%. Hence, morniflumate is demonstrated to reduce arachidonic acid metabolism, by exerting its effects on cyclooxygenase and 5-lipoxygenase. This characteristic might provide a better approach for anti-inflammatory therapy [A7899].

In several animal models orally administered morniflumate, the beta-morpholinoethyl ester of niflumic acid, proved almost equal to the parent compound in anti-inflammatory, analgesic and antipyretic activity with the absence of gastric irritating/ulcerogenic effects of its acidic parent compound [8].

Mechanism of action

The primary mechanism of niflumic acid and its ester is action is inhibition of enzymes involved in the synthesis of inflammatory prostaglandins [L14945]. This medication inhibits cyclooxygenase and 5-lipoxygenase pathways, which lead to fever and inflammation [11].

Niflumic acid, a calcium-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of inflammatory conditions. Niflumic acid does directly inhibit calcium channels or activate potassium channels. Niflumic acid selectively reduces noradrenaline- and 5-HT-induced pressor responses by inhibiting a mechanism which leads to the opening of voltage-gated calcium channels [11]. Niflumic acid (NFA) produces biphasic behavior on human CLC-K channels that suggests the presence of two functionally different binding sites: an activating site and a blocking site [11].

TargetActionsOrganism
UArachidonate 5-lipoxygenase
antagonist
Human
UProstaglandin G/H synthase 2Not AvailableHuman
ULeukotriene B4 receptor 1
antagonist
Human
UThromboxane A2 receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

Strongly bound to plasma proteins with approximately 100% bioavailability [10].

Metabolism

The pharmacokinetic availability of niflumic acid in two different pharmaceutical preparations have been studied in 12 subjects after oral administration [10].

Bioavailability and pharmacokinetics studies after oral and intravenous (IV) administration demonstrate that morniflumate is absorbed as from the gastrointestinal tract, followed by rapid hydrolysis in the plasma, releasing the free acidic form, the molecule responsible for its anti-inflammatory effects. The ester displays gastroprotective effect against the ulcerogenic effects of niflumic acid [8].

Route of elimination

0.12 L /kg on average [10]

Half life

2h [10]

Clearance

45 ml/min [10]

Toxicity

As with other anti-inflammatory medications, adverse effects may include: agranulocytosis, bleeding, hepatotoxicity, acute renal failure, dermatoses, and rarely angioedema and urticaria [8].

Early supportive management in addition to careful monitoring of urine output and renal function is essential for patients with heart failure, chronic kidney and liver disease, and in patients taking a diuretic after major surgery while taking this medication [6].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Morniflumate is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Morniflumate.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Morniflumate.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Morniflumate.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolMorniflumate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Adapalene.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Morniflumate.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Morniflumate.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Morniflumate.Experimental, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Alminoprofen.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Morniflumate.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Morniflumate.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Morniflumate.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Morniflumate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Antipyrine.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Morniflumate is combined with Apocynin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Morniflumate is combined with Apremilast.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Morniflumate.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Balsalazide.Approved, Investigational
BazedoxifeneMorniflumate may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Morniflumate.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bendazac.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Benzydamine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Morniflumate.Approved, Vet Approved
BevoniumThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bevonium.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bucillamine.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Morniflumate.Approved
BufexamacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bufexamac.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bumadizone.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Morniflumate is combined with Carbaspirin calcium.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Morniflumate is combined with Celecoxib.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorotrianiseneMorniflumate may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Morniflumate.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Morniflumate.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Morniflumate.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Morniflumate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Morniflumate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Morniflumate.Approved
ClonixinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Clonixin.Approved
ClorindioneMorniflumate may increase the anticoagulant activities of Clorindione.Experimental
Conjugated estrogensMorniflumate may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Morniflumate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Morniflumate.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Morniflumate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Morniflumate is combined with Curcumin.Approved, Investigational
DaidzeinMorniflumate may increase the thrombogenic activities of Daidzein.Experimental
DapoxetineDapoxetine may increase the antiplatelet activities of Morniflumate.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Morniflumate.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Morniflumate.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Morniflumate.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Morniflumate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Morniflumate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Morniflumate.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Morniflumate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Morniflumate.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Diclofenac.Approved, Vet Approved
DicoumarolMorniflumate may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolMorniflumate may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolMorniflumate may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Morniflumate.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Morniflumate is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Morniflumate.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Morniflumate.Approved
DiphenadioneMorniflumate may increase the anticoagulant activities of Diphenadione.Experimental
DroxicamThe risk or severity of adverse effects can be increased when Morniflumate is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Morniflumate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Morniflumate is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Morniflumate is combined with E-6201.Investigational
EpimestrolMorniflumate may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Morniflumate is combined with Epirizole.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Morniflumate.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Morniflumate.Approved
EquolMorniflumate may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Morniflumate.Approved, Investigational
EstradiolMorniflumate may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateMorniflumate may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateMorniflumate may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateMorniflumate may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolMorniflumate may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedMorniflumate may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneMorniflumate may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Morniflumate.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ethenzamide.Experimental
Ethinyl EstradiolMorniflumate may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateMorniflumate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etofenamate.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Morniflumate.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Morniflumate is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Morniflumate is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Feprazone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ferulic acid.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Floctafenine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Morniflumate.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Morniflumate.Approved, Investigational
FluindioneMorniflumate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Morniflumate.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Morniflumate.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Morniflumate.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Morniflumate.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Morniflumate.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Morniflumate.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Morniflumate.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Morniflumate.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Morniflumate.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Morniflumate.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Morniflumate.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Morniflumate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Morniflumate.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Morniflumate.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Morniflumate.Approved, Investigational, Withdrawn
GenisteinMorniflumate may increase the thrombogenic activities of Genistein.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Morniflumate is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Morniflumate.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Morniflumate.Investigational
HexestrolMorniflumate may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Higenamine.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Morniflumate.Approved, Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Morniflumate is combined with Icatibant.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Imidazole salicylate.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Morniflumate.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Indoprofen.Withdrawn
IsoxicamThe risk or severity of adverse effects can be increased when Morniflumate is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Morniflumate.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ketorolac.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Leflunomide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Morniflumate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lisofylline.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Morniflumate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Morniflumate is combined with Masoprocol.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Morniflumate.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Morniflumate.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mefenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Morniflumate.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Morniflumate is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mesalazine.Approved
MestranolMorniflumate may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Morniflumate is combined with Metamizole.Approved, Investigational, Withdrawn
MethallenestrilMorniflumate may increase the thrombogenic activities of Methallenestril.Experimental
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Morniflumate.Approved, Vet Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Morniflumate.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mizoribine.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Morniflumate.Approved, Vet Approved
MoxestrolMorniflumate may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nabumetone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Naftifine.Approved
NaproxenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Morniflumate.Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Morniflumate.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nepafenac.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nitroaspirin.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Morniflumate.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olsalazine.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Oxaprozin.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Oxyphenbutazone.Approved, Withdrawn
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Morniflumate.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Morniflumate is combined with Parecoxib.Approved
ParoxetineParoxetine may increase the antiplatelet activities of Morniflumate.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Parthenolide.Approved, Investigational
PhenindioneMorniflumate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMorniflumate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pimecrolimus.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pirfenidone.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Morniflumate is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pirprofen.Experimental
Polyestradiol phosphateMorniflumate may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Morniflumate.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Morniflumate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Morniflumate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Morniflumate.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Morniflumate.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Morniflumate.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Proglumetacin.Experimental
PromestrieneMorniflumate may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Morniflumate is combined with Propacetamol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Proquazone.Experimental
PTC299The risk or severity of adverse effects can be increased when Morniflumate is combined with PTC299.Investigational
QuinestrolMorniflumate may increase the thrombogenic activities of Quinestrol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Morniflumate is combined with Resveratrol.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Morniflumate.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Morniflumate is combined with Rofecoxib.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salsalate.Approved
SecoisolariciresinolMorniflumate may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Morniflumate is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Morniflumate is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Morniflumate is combined with Serrapeptase.Investigational
SertralineSertraline may increase the antiplatelet activities of Morniflumate.Approved
SRT501The risk or severity of adverse effects can be increased when Morniflumate is combined with SRT501.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Morniflumate is combined with Sulindac.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Morniflumate is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AMorniflumate may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BMorniflumate may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tarenflurbil.Investigational
TenidapThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tiaprofenic acid.Approved
TiboloneMorniflumate may increase the thrombogenic activities of Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tinoridine.Investigational
TioclomarolMorniflumate may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Morniflumate.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tolmetin.Approved
TranilastThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tranilast.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Morniflumate.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tribenoside.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Morniflumate is combined with Triptolide.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Morniflumate.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Morniflumate is combined with Valdecoxib.Approved, Investigational, Withdrawn
VenlafaxineVenlafaxine may increase the antiplatelet activities of Morniflumate.Approved
WarfarinMorniflumate may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Morniflumate is combined with Zaltoprofen.Approved, Investigational
ZeranolMorniflumate may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Morniflumate is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Morniflumate.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Morniflumate is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Melica A, Donateo L, Gerardi R, Parenti M: [A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis]. Riv Eur Sci Med Farmacol. 1991 Feb-Apr;13(1-2):51-60. [PubMed:1796197]
  2. Civelli M, Vigano T, Acerbi D, Caruso P, Giossi M, Bongrani S, Folco GC: Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9. [PubMed:1659152]
  3. Schiantarelli P, Cadel S, Acerbi D: A gastroprotective anti-inflammatory agent: the beta-morpholinoethyl ester of niflumic acid (morniflumate). Agents Actions. 1984 Feb;14(2):247-56. [PubMed:6608862]
  4. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6. [PubMed:16278927]
  5. Morniflumate [Link]
  6. Morniflumate [Link]
  7. Morniflumate induced urticaria and angioedema [Link]
  8. A gastroprotective anti-inflammatory agent: theβ-morpholinoethyl ester of niflumic acid (morniflumate) [Link]
  9. Modulation of arachidonic acid metabolism by orally administered morniflumate in man [Link]
  10. The pharmacokinetics and availability of niflumic acid in humans [Link]
  11. Niflumic acid [Link]
External Links
KEGG Drug
D05078
PubChem Compound
72106
PubChem Substance
310265178
ChemSpider
65089
ChEBI
136018
ChEMBL
CHEMBL2105059
Wikipedia
Morniflumate
ATC Codes
M01AX22 — Morniflumate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)75-77https://www.scbt.com/scbt/product/morniflumate-65847-85-0
water solubilitysoluble in DMSOhttps://www.medkoo.com/products/10883
Predicted Properties
PropertyValueSource
Water Solubility0.0861 mg/mLALOGPS
logP3.34ALOGPS
logP4.77ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)14.21ChemAxon
pKa (Strongest Basic)5.86ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.69 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity97.79 m3·mol-1ChemAxon
Polarizability38.37 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Pyridinecarboxylic acids / Aniline and substituted anilines / Aminopyridines and derivatives / Morpholines / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Trialkylamines / Amino acids and derivatives / Carboxylic acid esters
show 10 more
Substituents
Trifluoromethylbenzene / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aniline or substituted anilines / Aminopyridine / Morpholine / Oxazinane / Pyridine / Imidolactam / Heteroaromatic compound
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. A gastroprotective anti-inflammatory agent: theβ-morpholinoethyl ester of niflumic acid (morniflumate) [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Nucleotide binding
Specific Function
Receptor for extracellular ATP > UTP and ADP. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. May be the cardiac P2Y r...
Gene Name
LTB4R
Uniprot ID
Q15722
Uniprot Name
Leukotriene B4 receptor 1
Molecular Weight
37556.925 Da
References
  1. Modulation of arachidonic acid metabolism by orally administered morniflumate in man [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Thromboxane a2 receptor activity
Specific Function
Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messen...
Gene Name
TBXA2R
Uniprot ID
P21731
Uniprot Name
Thromboxane A2 receptor
Molecular Weight
37430.69 Da
References
  1. Modulation of arachidonic acid metabolism by orally administered morniflumate in man [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. A gastroprotective anti-inflammatory agent: theβ-morpholinoethyl ester of niflumic acid (morniflumate) [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. A gastroprotective anti-inflammatory agent: theβ-morpholinoethyl ester of niflumic acid (morniflumate) [Link]
3. UDP-glucuronosyltransferase 1A9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
References
  1. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6. [PubMed:16278927]

Drug created on October 29, 2015 12:08 / Updated on June 02, 2018 08:19